The Joint Corp.

NasdaqCM:JYNT Rapport sur les actions

Capitalisation boursière : US$172.2m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Joint Résultats passés

Passé contrôle des critères 0/6

Joint's earnings have been declining at an average annual rate of -41.6%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 21.7% per year.

Informations clés

-41.6%

Taux de croissance des bénéfices

-41.4%

Taux de croissance du BPA

Healthcare Croissance de l'industrie8.5%
Taux de croissance des recettes21.7%
Rendement des fonds propres-62.1%
Marge nette-12.0%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

The Joint Corp. (NASDAQ:JYNT) Shares Could Be 22% Above Their Intrinsic Value Estimate

Aug 05
The Joint Corp. (NASDAQ:JYNT) Shares Could Be 22% Above Their Intrinsic Value Estimate

Investors Could Be Concerned With Joint's (NASDAQ:JYNT) Returns On Capital

Jul 17
Investors Could Be Concerned With Joint's (NASDAQ:JYNT) Returns On Capital

Optimistic Investors Push The Joint Corp. (NASDAQ:JYNT) Shares Up 26% But Growth Is Lacking

May 04
Optimistic Investors Push The Joint Corp. (NASDAQ:JYNT) Shares Up 26% But Growth Is Lacking

The Joint Corp.'s (NASDAQ:JYNT) Share Price Not Quite Adding Up

Mar 10
The Joint Corp.'s (NASDAQ:JYNT) Share Price Not Quite Adding Up

Returns Are Gaining Momentum At Joint (NASDAQ:JYNT)

Feb 12
Returns Are Gaining Momentum At Joint (NASDAQ:JYNT)

Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To Continue

Jun 17
Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To Continue

Joint's (NASDAQ:JYNT) Returns On Capital Are Heading Higher

Jan 04
Joint's (NASDAQ:JYNT) Returns On Capital Are Heading Higher

Does Joint (NASDAQ:JYNT) Have A Healthy Balance Sheet?

Oct 27
Does Joint (NASDAQ:JYNT) Have A Healthy Balance Sheet?

The Joint Corp. Can Relieve You From High Inflation Pain

Oct 17

The Joint Corp.: Weakening Bottom-Line Fundamentals Unsupportive In Current Landscape

Aug 05

These 4 Measures Indicate That Joint (NASDAQ:JYNT) Is Using Debt Reasonably Well

Jul 22
These 4 Measures Indicate That Joint (NASDAQ:JYNT) Is Using Debt Reasonably Well

Returns Are Gaining Momentum At Joint (NASDAQ:JYNT)

Jun 29
Returns Are Gaining Momentum At Joint (NASDAQ:JYNT)

Is There Now An Opportunity In The Joint Corp. (NASDAQ:JYNT)?

Jun 14
Is There Now An Opportunity In The Joint Corp. (NASDAQ:JYNT)?

Joint's (NASDAQ:JYNT) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Mar 03
Joint's (NASDAQ:JYNT) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Should You Be Adding Joint (NASDAQ:JYNT) To Your Watchlist Today?

Feb 23
Should You Be Adding Joint (NASDAQ:JYNT) To Your Watchlist Today?

Does Joint (NASDAQ:JYNT) Have A Healthy Balance Sheet?

Feb 08
Does Joint (NASDAQ:JYNT) Have A Healthy Balance Sheet?

Joint Corp.: Solid Q4 Results From This Small-Cap Growth Story

Jan 30

Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To Continue

Jan 24
Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To Continue

What Does The Joint Corp.'s (NASDAQ:JYNT) Share Price Indicate?

Jan 08
What Does The Joint Corp.'s (NASDAQ:JYNT) Share Price Indicate?

Do Joint's (NASDAQ:JYNT) Earnings Warrant Your Attention?

Nov 23
Do Joint's (NASDAQ:JYNT) Earnings Warrant Your Attention?

Is Joint (NASDAQ:JYNT) A Risky Investment?

Nov 08
Is Joint (NASDAQ:JYNT) A Risky Investment?

Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To Continue

Oct 21
Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To Continue

Is The Joint Corp. (NASDAQ:JYNT) Potentially Undervalued?

Oct 05
Is The Joint Corp. (NASDAQ:JYNT) Potentially Undervalued?

The Joint Corporation: Time To Take Some Profits

Aug 10

Is Joint (NASDAQ:JYNT) Using Too Much Debt?

Aug 02
Is Joint (NASDAQ:JYNT) Using Too Much Debt?

The Joint Corp. Has Rallied By 400% Since We Bought, But It's Time To Let It Go

Jul 23

Ventilation des recettes et des dépenses

Comment Joint gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqCM:JYNT Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 24120-141010
31 Mar 24119-11980
31 Dec 23118-10980
30 Sep 231152950
30 Jun 231124920
31 Mar 231073900
31 Dec 221011840
30 Sep 22950820
30 Jun 22892760
31 Mar 22855690
31 Dec 21808620
30 Sep 217618550
30 Jun 217017500
31 Mar 216315460
31 Dec 205913440
30 Sep 20564430
30 Jun 20533410
31 Mar 20513400
31 Dec 19483370
30 Sep 19452350
30 Jun 19412330
31 Mar 19391310
31 Dec 18370300
30 Sep 1834-1280
30 Jun 1831-1260
31 Mar 1828-2240
31 Dec 1725-3230
30 Sep 1724-9230
30 Jun 1723-11250
31 Mar 1722-13260
31 Dec 1621-15260
30 Sep 1619-13260
30 Jun 1617-12240
31 Mar 1616-10210
31 Dec 1514-9190
30 Sep 1512-8150
30 Jun 1510-7120
31 Mar 158-590
31 Dec 147-360
30 Sep 147050
30 Jun 146040
31 Mar 146040
31 Dec 136030

Des revenus de qualité: JYNT is currently unprofitable.

Augmentation de la marge bénéficiaire: JYNT is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: JYNT is unprofitable, and losses have increased over the past 5 years at a rate of 41.6% per year.

Accélération de la croissance: Unable to compare JYNT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: JYNT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6%).


Rendement des fonds propres

ROE élevé: JYNT has a negative Return on Equity (-62.07%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé